# Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

> **NCT02275338** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 52 (actual)

## Conditions studied

- Intestinal Obstruction

## Interventions

- **DRUG:** Lanreotide Autogel

## Key facts

- **NCT ID:** NCT02275338
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-19
- **Primary completion:** 2017-11-09
- **Final completion:** 2017-11-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02275338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02275338, "Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02275338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*